Eledon Pharmaceuticals, Inc. (ELDN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ELDN
- Company Eledon Pharmaceuticals, Inc.
- Price $2.51
- Changes Percentage 10.35
- Change 0.24
- Day Low $2.27
- Day High $2.62
- Year High $4.6
- Year Low $1.35
- Market Cap $150,172,979
- Price Avg 50 EMA (D) $1.9
- Price Avg 200 EMA (D) $2.6
- Exchange NASDAQ
- Volume 1,441,830
- Average Volume 831,785
- Open $2.33
- Previous Close $2.27
- EPS -1.3
- PE -1.93
- Earnings Announcement 2026-03-19 21:00:00
- Shares Outstanding $59,949,293
Company brief: ELEDON PHARMACEUTICALS, INC. (ELDN )
- Healthcare
- Biotechnology
- Dr. David-Alexandre C. Gros M.D., Ph.D.
- https://eledon.com
- US
- N/A
- 09-17-2014
- US28617K1016
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.